Search Results - "Chu, Quincy S.C."

Prolonged Response to Regorafenib in a Patient with Iodine Refractory Thyroid Cancer by Wong, Selina K., Chu, Quincy S.C., Spratlin, Jennifer L., Sangha, Randeep, McEwan, Alexander J.B., Morrish, Donald W., Arndt, Diane, Sergenson, Gwen, Cleton, Adriaan, Huang, Funan, Sawyer, Michael B.

“…Thyroid cancer is the most common type of endocrine malignancy. Cornerstones of thyroid cancer treatment include surgery, radioactive iodine ablation, and…”
Get full text

How Is Receptor Activator of Nuclear Factor-κβ/Receptor Activator of Nuclear Factor-κβ Ligand Targeting Ranked as an Immuno-Oncology Target for NSCLC: a Pathway Unclear as yet? by Chu, Quincy S C

Get more information

A Phase I and Pharmacokinetic Study of Lapatinib in Combination with Letrozole in Patients with Advanced Cancer by Chu, Quincy S C, Cianfrocca, Mary E, Goldstein, Lori J, Gale, Meg, Murray, Nicholas, Loftiss, Jill, Arya, Nikita, Koch, Kevin M, Pandite, Lini, Fleming, Ronald A, Paul, Elaine, Rowinsky, Eric K

“…Purpose: The main objectives of this phase I and pharmacokinetic, open-label study were to determine the optimally tolerated regimen (OTR), safety,…”
Get full text

Phase I and Pharmacokinetic Study of Lapatinib in Combination With Capecitabine in Patients With Advanced Solid Malignancies by CHU, Quincy S. C, SCHWARTZ, Garry, HO, Peter T. C, ROWINSKY, Eric K, DE BONO, Johann, SMITH, Deborah A, KOCH, Kevin M, VERSOLA, Melissa J, PANDITE, Lini, ARYA, Nikita, CURTRIGHT, Jan, FLEMING, Ronald A

“…This phase I trial (EGF10005) assessed the safety, optimally tolerated regimen (OTR), and pharmacokinetics of lapatinib and capecitabine in combination in…”
Get full text

Phase I and Pharmacokinetic Study of Tasidotin Hydrochloride (ILX651), a Third-Generation Dolastatin-15 Analogue, Administered Weekly for 3 Weeks Every 28 Days in Patients with Advanced Solid Tumors by MITA, Alain C, HAMMOND, Lisa A, WEITMAN, Steve, ROWINSKY, Eric K, BONATE, Peter L, WEISS, Geoffrey, MCCREERY, Heather, SYED, Samira, GARRISON, Mitchell, CHU, Quincy S. C, DEBONO, Johann S, JONES, Christopher B

“…Purpose: To determine the safety, tolerability, and pharmacokinetics and to seek preliminary evidence of anticancer activity of tasidotin (ILX651), a novel…”
Get full text

Supplementation with fish oil increases first‐line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer by Murphy, Rachel A., Mourtzakis, Marina, Chu, Quincy S. C., Baracos, Vickie E., Reiman, Tony, Mazurak, Vera C.

“…BACKGROUND: Palliative chemotherapy is aimed at increasing survival and palliating symptoms. However, the response rate to first‐line chemotherapy in patients…”
Get full text

Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy by Murphy, Rachel A., Mourtzakis, Marina, Chu, Quincy S.C., Baracos, Vickie E., Reiman, Tony, Mazurak, Vera C.

“…BACKGROUND: Involuntary weight loss is a major contributor to mortality and morbidity in patients with advanced cancer. Nutritional intervention with fish oil…”
Get full text

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial by Besse, Benjamin, Pons-Tostivint, Elvire, Park, Keunchil, Hartl, Sylvia, Forde, Patrick M., Hochmair, Maximilian J., Awad, Mark M., Thomas, Michael, Goss, Glenwood, Wheatley-Price, Paul, Shepherd, Frances A., Florescu, Marie, Cheema, Parneet, Chu, Quincy S. C., Kim, Sang-We, Morgensztern, Daniel, Johnson, Melissa L., Cousin, Sophie, Kim, Dong-Wan, Moskovitz, Mor T., Vicente, David, Aronson, Boaz, Hobson, Rosalind, Ambrose, Helen J., Khosla, Sajan, Reddy, Avinash, Russell, Deanna L., Keddar, Mohamed Reda, Conway, James P., Barrett, J. Carl, Dean, Emma, Kumar, Rakesh, Dressman, Marlene, Jewsbury, Philip J., Iyer, Sonia, Barry, Simon T., Cosaert, Jan, Heymach, John V.

“…For patients with non-small-cell lung cancer (NSCLC) tumors without currently targetable molecular alterations, standard-of-care treatment is immunotherapy…”
Get full text

Present and Emerging Biomarkers in Immunotherapy for Metastatic Non-Small Cell Lung Cancer: A Review by Khwaja, Raida M, Chu, Quincy S-C

“…Targeting the immune system, especially the PDL-1/PD-1 axis, has significantly improved the outcomes of metastatic lung cancer patients. However, only a…”
Get full text

Determinants of change in resting energy expenditure in patients with stage III/IV colorectal cancer by Purcell, Sarah A., Wallengren, Ola, Baracos, Vickie E., Lundholm, Kent, Iresjö, Britt-Marie, Chu, Quincy S.C., Ghosh, Sunita S., Prado, Carla M.

“…Resting energy expenditure (REE) is variable in cancer and might be influenced by changes in tumor burden, systemic inflammation, and body composition. The…”
Get full text

An Open-Label, Phase II Study of the Polo-like Kinase-1 (Plk-1) Inhibitor, BI 2536, in Patients with Relapsed Small Cell Lung Cancer (SCLC) by Awad, Mark M, Chu, Quincy S-C, Gandhi, Leena, Stephenson, Joe J, Govindan, Ramaswamy, Bradford, Daniel S, Bonomi, Philip D, Ellison, David M, Eaton, Keith D, Fritsch, Holger, Munzert, Gerd, Johnson, Bruce E, Socinski, Mark A

“…Highlights • BI 2536 inhibits polo-like kinase 1 (Plk-1), a critical regulator of the cell cycle. • Plk inhibitors prevent growth of several small cell lung…”
Get full text

Accuracy of Resting Energy Expenditure Predictive Equations in Patients With Cancer by Purcell, Sarah A., Elliott, Sarah A., Baracos, Vickie E., Chu, Quincy S. C., Sawyer, Michael B., Mourtzakis, Marina, Easaw, Jacob C., Spratlin, Jennifer L., Siervo, Mario, Prado, Carla M.

“…Background Our purpose was to assess the accuracy of resting energy expenditure (REE) equations in patients with newly diagnosed stage I–IV non–small cell…”
Get full text

Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung Cancer by Ionescu, Diana N, Stockley, Tracy L, Banerji, Shantanu, Couture, Christian, Mather, Cheryl A, Xu, Zhaolin, Blais, Normand, Cheema, Parneet K, Chu, Quincy S-C, Melosky, Barbara, Leighl, Natasha B

“…Non-small cell lung cancer (NSCLC) has historically been associated with a poor prognosis and low 5-year survival, but the use of targeted therapies in NSCLC…”
Get full text

Profiling Determinants of Resting Energy Expenditure in Colorectal Cancer by Purcell, Sarah A., Baracos, Vickie E., Chu, Quincy S.C., Sawyer, Michael B., Severin, Diane, Mourtzakis, Marina, Lieffers, Jessica R., Prado, Carla M.

“…Background: Understanding resting energy expenditure (REE) is important for determining energy requirements; REE might be altered in individuals with cancer…”
Get full text

Predictive Impact of Clinical Benefit in Chemotherapy-treated Advanced Pancreatic Cancer Patients in Northern Alberta by Kim, Christina A, Chu, Quincy S C, Fassbender, Konrad, Ghosh, Sunita, Spratlin, Jennifer L

“…Patients with advanced pancreatic cancer (APC) have a poor prognosis and experience a large burden of disease-related symptoms. Despite advancements in the…”
Get full text

Canadian Consensus Recommendations on the Management of Extensive-Stage Small-Cell Lung Cancer by Melosky, Barbara L, Leighl, Natasha B, Dawe, David, Blais, Normand, Wheatley-Price, Paul F, Chu, Quincy S-C, Juergens, Rosalyn A, Ellis, Peter M, Sun, Alexander, Schellenberg, Devin, Ionescu, Diana N, Cheema, Parneet K

“…Small-cell lung cancer (SCLC) is an aggressive, neuroendocrine tumour with high relapse rates, and significant morbidity and mortality. Apart from advances in…”
Get full text

Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC by Cheema, Parneet K, Banerji, Shantanu O, Blais, Normand, Chu, Quincy S-C, Juergens, Rosalyn A, Leighl, Natasha B, Sacher, Adrian, Sheffield, Brandon S, Snow, Stephanie, Vincent, Mark, Wheatley-Price, Paul F, Yip, Stephen, Melosky, Barbara L

“…Activating mutations in , in particular, a point mutation leading to a glycine-to-cysteine substitution at codon 12 (G12C), are among the most frequent genomic…”
Get full text

Canadian Consensus Recommendations on the Management of MET -Altered NSCLC by Cheema, Parneet K, Banerji, Shantanu O, Blais, Normand, Chu, Quincy S-C, Desmeules, Patrice, Juergens, Rosalyn A, Leighl, Natasha B, Sheffield, Brandon S, Wheatley-Price, Paul F, Melosky, Barbara L

“…In Canada, the therapeutic management of patients with advanced non-small cell lung cancer (NSCLC) with rare actionable mutations differs between provinces,…”
Get full text

Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours by Devriese, Lot A., Koch, Kevin M., Mergui-Roelvink, Marja, Matthys, Gemma M., Ma, Wen Wee, Robidoux, Andre, Stephenson, Joe J., Chu, Quincy S. C., Orford, Keith W., Cartee, Leanne, Botbyl, Jeff, Arya, Nikita, Schellens, Jan H. M.

“…Summary Aim To quantify the effect of food on the systemic exposure of lapatinib at steady state when administered 1 h before and after meals, and to observe…”
Get full text

UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib by Meza-Junco, Judith, Chu, Quincy S.-C, Christensen, Olaf, Rajagopalan, Prabhu, Das, Soma, Stefanyschyn, Ruslan, Sawyer, Michael B

“…Purpose To report a single case of uridine glucuronosyltransferase 1A1 (UGT1A1) polymorphism and hyperbilirubinemia in a patient who received sorafenib…”
Get full text